Bronchiolitis obliterans syndrome (BOS) is one of most frequent late-onset non-infectious pulmonary complication after allogeneic hematopoietic stem cell transplantation. It occurs in~14% of patients with cGvHD, 1 usually within the first 2 years from transplant (but also several years later), and is characterised by high morbidity and mortality (5-year survival rate of 45 vs 75% in patients without BOS). 2, 3 BOS is defined by the onset of progressive airflow obstruction in the absence of respiratory infection, usually correlated with the pathological pattern of obliterative bronchiolitis. At early stages, patients can be asymptomatic; later in the course of disease, respiratory infections or chest constriction due to advanced sclerotic GvHD or intrapulmonary processes may hinder the correct diagnosis. 4, 5 Current treatment of BOS (macrolides, change or increase in immunosuppression-mainly steroids-and inhaled therapy 6 ) still remains unsatisfactory with high mortality rates. 7 Recently, extracorporeal photopheresis (ECP) has been reported as a promising option for treatment of BOS in two case series. 8, 9 We report our preliminary experience on 13 chronic GvHD (cGvHD) patients with BOS refractory to standard treatment, treated with ECP in association to standard therapy.
We retrospectively assessed the medical records of all cGvHD patients with BOS treated by ECP between February 2009 and April 2015 (n = 13): seven had symptomatic BOS before starting ECP (group A) and were referred to our service after failure of immunosuppressive and supportive therapy ((Fluticasone (250 μg/day), azithromycin (250 mg on alternate days), montelukast (10 mg/day)). The remaining six patients (group B) developed BOS while on treatment by ECP for cGVHD not responsive to immunosuppressive therapy. After BOS diagnosis (according to NIH criteria 10 ), ECP was maintained with the same schedule as before BOS diagnosis and patients underwent the same supportive therapy as for group A. ECP sessions were escalated (following the same schedule as for group A) when patients did not respond to supportive therapy.
Patients' characteristics for group A and B are detailed in Table 1 . All patients were symptomatic at the time of diagnosis, with dyspnoea as the most common symptom, often associated with productive cough. Active respiratory infections at the time of diagnosis were excluded by microbiological and viral testing on sputum or broncho-alveolar lavage and CT scans. No patient underwent lung biopsy.
All patients referred for ECP (using the off-line technique, as previously described 11 ) have been treated independently from BOS grade, oxygen therapy and haemoglobin level. ECP treatment schedule for group A followed that one adopted in our centre for chronic lung allograft dysfunction (CLAD) patients: 12 1 cycle (that is, two apheresis sessions) per week for 3 weeks, 1 cycle fortnightly for 3 times, 1 cycle per month if improvement/stabilisation. For group B, immediately after the diagnosis of BOS, ECP cycles were intensified and followed the schedule described above for group A.
Duration of apheresis sessions is~2 h. ECP treatment was temporarily suspended for those patients with evidence of systemic infection and/or absolute MNCs count o200 × 10 9 /L. In both groups, response was assessed 3 months after ECP start (Group A) or intensification (Group B). Patient reported pulmonary symptoms were recorded. Pulmonary function was assessed by spirometry considering the FEV1 as the sole parameter. Since pulmonary function tests were performed without a regular schedule, we adopted linear regression models to estimate the rate of FEV1 slope (in mL/month) before and after treatment with ECP: 3-16 months before ECP → pre-baseline; 0-3 months before the beginning of ECP → baseline (pre-treatment); 6-15 months after ECP → post-treatment. Response was defined as complete if the rate of FEV1 decline became positive (the FEV1 curve inverted its slope)' and partial if post treatment the rate of FEV1 decline slowed down as compared with pre-ECP or pre-ECP intensification. No response was defined as any rate of worsening of FEV1 decline. In group A, ECP was started at a median of 12 months (range 2-17 months) after BOS diagnosis, with a median of 34 procedures for patient (range 13-59). The median time of follow-up since ECP was 15 months (range 8-72 months). No patient withdrew from ECP during follow-up.
We have not been able to assess the functional response in 1 patient because no FEV1 measurement in the 0-3 months before ECP was available. Functional response was achieved in six out of six patients (complete n = 4; partial n = 2 at a median of 8.5 and 3 months, respectively; Figure 1a ) while improvement of symptoms was obtained in six out of seven patients. At the end of follow-up all responder patients were able to maintain response. Prednisone was tapered during ECP in four patients.
In group B, ECP was started at a median of 1.5 months (range 0-3) after GVHD diagnosis, for a median overall treatment duration of 7 months (range 5-20) and a median of 48.5 procedures per patient (range 20-60). BOS occurred after ECP frequency was delayed at 1 cycle/month due to good response in the other organs affected, after a median of 9 months (range 3-24) from ECP start. Lung functional response after ECP intensification was obtained in four out of six patients (complete n = 3 and partial n = 1, at a median of 4 and 3 months, respectively) (Figure 1b) with an improvement of symptoms in five out of six patients. The median time of follow-up since ECP was 11.3 months (range 6-26 months). One patient who did not respond withdrew from ECP because of disease relapse. Like group A, all responder patients at the end of follow-up were able to maintain the response. Prednisone was tapered in three patients.
During ECP, no MNCs reinfusion-related adverse events and no transfusion requirement occurred. All patients were alive at last follow-up.
Recent retrospective studies have reported high mortality rates in patients diagnosed with BOS and cGVHD regardless of therapy.
immunomodulatory properties of ECP demonstrated a positive impact in both acute and chronic GvHD, in CLAD and, more recently, in two small retrospective case series of cGvHD patients with BOS. 8, 9 Our experience on 13 patients supports the evidence on ECP efficacy in slowing lung function decline, also in patients treated at more advanced stages of BOS. Similarly to Brownback et al. 11 , we have been able to taper immunosuppressive therapy (mainly steroids) in responsive patients, with obvious advantages especially on the infection risk. In our small cohort, ECP was effective in reversing or slowing the FEV1 rate of decline in patients who started ECP following the BOS diagnosis owing to no response to standard and supportive treatment. Interestingly, encouraging results were obtained also after ECP intensification, when BOS occurred while on chronic treatment with ECP (two procedures/month) for cGvHD with other organs involved not responsive to standard treatment. All responders maintained the response at the end of follow-up. The decision to increase the frequency of ECP sessions had been taken based on the good results obtained during our 10 years experience in treatment of CLAD in lung transplant recipients by ECP. 12 A possible explanation of the positive impact on BOS after ECP intensification may be the higher number of cells treated over time and consequently the more intense and lasting immunomodulation. Moreover, our results in the larger cohort of patients with CLAD treated by ECP are similar to those reported in the present study, thus suggesting that lung GvHD and BOS after lung transplantation are similar clinical and pathophysiological entities. 13 The high association of BOS with cGvHD in other organs (for example, skin, liver and eyes) suggests that the same donor T cells are involved in development of lung injury.
14 As cGvHD with multiorgan involvement is a heterogeneous disease whose course is affected by multiple variables (for example,immune recovery, therapy, conditioning regimen and others) diverse-induced immunomodulatory patterns could explain the different response to ECP treatment (more or less intense) for group A and B in our study and also some contradictory data reported in literature. 15 Finally, based on the patient's delayed perception and the nonspecificity of clinical symptoms and findings on physical examination, a standardized approach is necessary for an early diagnosis of BOS, that is, before irreversible structural changes have occurred. In addition, infectious causes need to be ruled out.
In conclusion, notwithstanding the several limitations of our small case series, preliminary results appear to confirm the good response to ECP treatment reported by others. 8, 9 In addition, based on the encouraging results obtained after ECP intensification, we propose to closely monitor cGvHD patients for early diagnosis, and, in case of BOS, to promptly start ECP (in association with standard therapy) with an intensive ECP schedule, also considering the excellent tolerability of this therapy. Further studies are urgently needed to definitely prove the efficacy and to assess the optimal schedule of ECP treatment. and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to 
